Literature DB >> 35731350

Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma.

Qiwei Zhang1, Weiwei Rui2, Yongsheng Jiang3, Fei Yuan2, Yong Chen4, Xiaoxia Guo1, Yu Zhou1, Zhiyuan Wu5, Chaofu Wang6, Xiaoyi Ding7.   

Abstract

PURPOSE: OX40 signaling pathway occupies a vital place in anti-tumor immunity; however, the role of tumor-infiltrating OX40+ lymphocytes in pancreatic ductal adenocarcinoma (PDAC) remains to be identified.
METHODS: A total of 325 sequential PDAC patients who received curative tumor resection between January 2014 and December 2016 were enrolled. Tissues of these patients were immunohistochemically assessed for tumor infiltration of CD4+ T cells, CD8+ cytotoxic T cells (CTLs), and OX40+ lymphocytes. The frequency of OX40+ tumor-infiltrating lymphocytes (TILs) was then analyzed to various clinicopathological features, densities of tumor infiltration of CD4+ T cells and CTLs, and survival analysis was conducted using Kaplan-Meier (KM) curves. The risk scores of associated markers were calculated by the Cox proportional-hazards model.
RESULTS: Our results showed that higher OX40+ lymphocytes infiltration was significantly correlated with superior median overall survival (OS) (25.8 vs 13.4 months, P < 0.001). Additionally, using univariate and multivariate Cox proportional hazards analyses, this study revealed that together with tumor differentiation, tumor size, serum CA199 levels, serum CA125 levels, and the infiltration of intratumoral CD8+ T cells. The abundance of OX40+ lymphocytes within the tumor was continued to be an independent predictor for OS (P = 0.023, HR = 0.713, 95% CI: 0.532-0.954).
CONCLUSIONS: This study demonstrated that intratumoral infiltration by a high number of OX40+ lymphocytes is a novel biomarker for favorable prognosis in resected PDAC patients, which implies that OX40-agonist-based immunotherapy might be a potential target in PDAC patients.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  CD8+ cytotoxic T cells; Immunotherapy; OX40+ lymphocytes; Pancreatic ductal adenocarcinoma; Prognostic factor; Tumor microenvironment

Mesh:

Year:  2022        PMID: 35731350     DOI: 10.1007/s12094-022-02864-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  43 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

Authors:  Anand Mahadevan; Rebecca Miksad; Michael Goldstein; Ryan Sullivan; Andrea Bullock; Elizabeth Buchbinder; Douglas Pleskow; Mandeep Sawhney; Tara Kent; Charles Vollmer; Mark Callery
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-12       Impact factor: 7.038

Review 5.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

6.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

Authors:  Devin Schellenberg; Jeff Kim; Claudia Christman-Skieller; Carlene L Chun; Laurie Ann Columbo; James M Ford; George A Fisher; Pamela L Kunz; Jacques Van Dam; Andrew Quon; Terry S Desser; Jeffrey Norton; Annie Hsu; Peter G Maxim; Lei Xing; Karyn A Goodman; Daniel T Chang; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-05       Impact factor: 7.038

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 8.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

9.  Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

Authors:  R J Geer; M F Brennan
Journal:  Am J Surg       Date:  1993-01       Impact factor: 2.565

10.  The National Cancer Data Base report on pancreatic cancer.

Authors:  J E Niederhuber; M F Brennan; H R Menck
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.